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Morphological changes in human serum albumin in presence of 
cationic amphiphilic drugs  
Z. Yaseen,a† V. K. Aswal,b X. Zhou,d Kabir-ud-Din c and S. Haider d†  
Human serum albumin (HSA) is one of the most important carrier proteins present in the blood and can 
constitute more than half of serum proteins. It transports various biomolecules including hormones, fatty 
acids, ions, drugs and functions to regulate oncotic pressure in the plasma. Cationic amphiphillic drugs like 
amitriptyline hydrochloride, imipramine hydrochloride and promethazine hydrochloride bind to HSA and 
influences function by altering its conformation, as confirmed by Small-angle neutron scattering (SANS) data 
coupled to dynamic light scattering measurements (DLS). Protein unfolding was observed by SANS results 
through an increase in the value of the radius of gyration Rg. At higher drug concentrations, there was no 
change in the dimensions of the protein. However, the drugs formed free aggregates at higher 
concentrations without any growth in the drug micelles, which was confirmed by the appearance of second 
peak in DLS measurements. Molecular docking revealed that the morphology of hydrophobic moiety of the 
cationic amphiphilic drugs decides their binding fate with HSA, while trajectories from molecular dynamics 
simulations highlight structural disorder in the drug-HSA complex. 
Introduction  
Proteins are considered to be most important, abundant and 
versatile macromolecules, whose functions depends on its three 
dimensional structure1. Most drugs are small compounds that 
target and interact with proteins to induce perturbations in the 
protein function2. The binding of a drug to bio-molecules not only 
provides information regarding drug action (both toxic and 
therapeutic) but also sheds light on disposition and transport of 
drugs, which are regulated by various proteins such as human 
serum albumin (HSA). Detailed understanding of drug-protein 
binding is important from structural as well as dynamic point of 
views. Protein binding profiles of drugs are also useful in predicting 
potential side effects of the drugs. Thus, an understanding of the 
possible interactions between drug molecules and proteins is 
essential, in order to develop safe-engineered and biocompatible 
drug delivery 3-5. 
 
HSA is the major extracellular protein in blood plasma with a 
concentration of 40 mg ml-1. It has high affinity for a wide range of 
metabolites including drugs and transports various solutes into the 
blood stream. Thus, functioning to maintain the pH  
 
and oncotic pressure6. In this context, various researchers have 
attempted to utilize HSA as carrier to deliver various drugs to their 
specific target organs, in addition to their clinical usage in 
hypovolemic shock treatment7.  
   
 
 
Figure 1: Structure of human serum albumin (HSA) with docked 
drugs. The cationic drugs bind in an orientation very similar to 
diclofenac (PDB id 4Z69) in site 1 and diazepam (PDB id 2BXF) in site 
2. Detailed description of HSA-drug interactions in site 1/2 are 
illustrated in Supplementary figure S1. 
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HSA is a single non-glycosylated, 67kD polypeptide; in globular 
form, the protein is composed of three structurally similar domains 
(I-III), each consisting of two subdomains (A and B) and stabilized by 
17 disulfide bonds 7-13 (Figure 1). Several ion-pair interactions are 
also present at the interface region between domains 
(Supplementary figure S2). These ion-pair interactions and disulfide 
bridges impart rigidity to the structure, but at the same time, allow 
sufficient flexibility for the protein to undergo conformational 
changes based on the experimental conditions 14. The two major 
binding regions of HSA, namely drug sites 1 and 2, are located in 
subdomains IIA and IIIA, respectively 15 (Figure 1, Supplementary 
figure S2). Taking into account the wide range of effective 
concentrations of therapeutic drugs from μM to mM and high 
concentration of albumin, the free concentration for a therapeutic 
effect can be significantly reduced for drugs with high binding to 
plasma. It is of interest to characterize the structure of the 
complexes between serum albumins and drugs in order to find out 
the means by which clinical efficacy of drugs can be tuned. 
 
 
Figure 2: Chemical structures of cationic drugs imipramine 
hydrochloride (IMP), amitriptyline hydrochloride (AMT) and 
promethazine hydrochloride (PMT) used in this study. 
 
In the present study we have used small-angle neutron scattering 
data (SANS) coupled with dynamic light scattering (DLS) and 
molecular docking and simulations (MD) to explore the structural 
and dynamic interactions of HSA with three cationic amphiphilic 
drugs (amitriptyline hydrochloride (AMT), imipramine 
hydrochloride (IMP) and promethazine hydrochloride (PMT); Figure 
2). The group belonging to cationic amphiphilic drugs (CADs) is 
sizeable and includes many different therapeutic categories. Some 
of them are antidepressants, antiarrythmetic, antiginals, 
antibacterial, anoxeric, antipsychotic, and others 16. The three drugs 
used here represent an interesting variety of amphiphilic structures. 
At one extreme they resemble with typical surfactants as they have 
well defined cmc (critical micelle concentration); however, they 
form stacked type of aggregates, unlike that of surfactants, which 
mostly form spheroidal aggregates 17. The cmc values of AMT, IMP 
and PMT are 0.036, 0.040 and 0.045 M respectively 18. Earlier 
studies on surfactant–protein binding proposed formation of 
micelle-like aggregates which enclose the hydrophobic patches (of 
the surfactant) on the protein backbone and thus result in necklace-
bead structure of the protein-surfactant complex. In spite the fact 
that interactions between proteins and amphiphiles (especially 
surfactants) are well studied, the characterization of the complexes 
is still debated. At high surfactant concentrations, the proposed 
structures are: (a) “necklace and bead model” in which surfactant 
micelles are arranged along a polypeptide 19, (b) the rod-particle 
model where the amphiphile binding leads to expansion into a high 
aspect ratio prolate ellipsoidal 20, (c) flexible cylindrical micelle 
model where the protein molecule wraps around the surface of 
cylindrical micelles 21, and (d) a fractal arrangement of relatively 
small surfactant micelles bound to polypeptide chain, analogous to 
micellar model 22. Characterizing the complexes between protein 
and amphiphilic drugs (stacked type of aggregates) is of significance 
from a biomedical point of view. It is also pertinent to mention that 
small-angle neutron scattering characterization of amphiphilic drug-
protein complexes is sparsely reported in the literature. 
Results and discussion  
The SANS data for 1 wt % pure HSA and that of HSA incubated in 
the presence of the cationic drugs (from pre-micellar to post-
micellar region) are shown in Figure 3. The solid lines are fit to the 
SANS data using an ellipsoid model with the fitted parameters listed 
in Table 1. The data of pure HSA has been fitted to prolate 
ellipsoidal model and the fitting generated a value of semi major 
axis (a) = 70.1Å and that of semi minor axis (b=c) = 18.2Å, which are 
in good agreement with that of the reported values 23. SANS data 
show an increase in scattering cross-section with an increase in the 
drug concentration. 
 
As observed from Figure 3A, there is continuous increase in the 
scattering cross-section with an increase in drug concentration and 
the functionality of scattering pattern of drug-protein complexes is 
different from that of the protein. This change in scattering pattern 
at low-Q values can be interpreted in terms of the unfolding of 
protein. Figure 3B presents the scattering data as a Kratky plot 
representation (I(Q).(Q2) vs Q) of HSA(apo) and HSA-drug 
complexes. Evidently, the depicted data can be grouped into two 
sets, low concentration regime (25 mM and 50 mM) and high 
concentration regime (100 mM and 200 mM). The first data set 
corresponds to HSA(apo) at low drug concentrations where the 
scattering pattern is similar to that of free HSA at high-Q values. 
However, there is noticeable change at low-Q values, indicating 
formation of larger structures. Based on the knowledge of 
conventional surfactant binding to the protein molecules, we tried 
to fit the data by using the necklace model of protein-surfactant 
complexes that assumes micelle-like clusters of surfactants 
randomly distributed along the unfolded polypeptide chain, but 
failed completely. The data were then fitted by using random coil 
Gaussian conformation, which assumes drug molecules’ binding 
individually to the HSA, resulting in the opening of the globular 
protein structure into a random coil of the unfolded polypeptide 
chain, hence, leading to increase in the volume of the scattering 
particle. Data in Table 1 also suggest increase in radius of gyration 
(Rg) of the protein with increase in concentration of the drugs from 
25 mM to 50 mM.  In our earlier studies 24,25, we have reported that 
amphiphilic drug molecules (like AMT) form stacked type of micelles 
with aggregation number of 4-5 molecules, which is quite low in 
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comparison to that of conventional surfactants. The low 
aggregation number is due to the bulky hydrophobic backbone of 
drug molecules. Once the drug molecules bind to the HSA 
molecules, the hydrophobic backbone of drug molecules gets 
stabilized in hydrophobic pouches of the protein (not available for 
the aggregation). Hence, the drug molecules individually bind to the 
HSA, leading to unfolding of the polypeptide chain. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: (A) SANS data (B) Kratky plots and (C) Average 
hydrodynamic radii of 1wt% HSA(apo) and HSA-drug complexes. 
The rows correspond to (i) HSA-AMT (ii) HSA-PMT and (iii) HSA-IMP. 
 
Recently, Dey et al.26 reported that at high sodium salicylate and 
amphihphilic sodium deoxycholate concentration, the protein fibrils 
rearrange to random coil conformations (sodium deoxycholate also 
possesses a bulky hydrophobic backbone). Kiselev et al., have 
reported the size of HSA in 150mM NaCl to be ~27.4 ± 0.35 Å by 
SANS technique27.  The increase in Rg up to 52.88 ± 1 Å in presence 
of 25mM AMT (and similar changes with HSA-IMP and HSA-PMT 
systems, Table 1) indicates that the drug causes unfolding of the 
HSA molecule28. The drug molecules bind to the hydrophobic 
pockets of protein in between the sub-domains. Hence, the sub-
domains of protein start separating from each other after adding 
the drug, which leads to increase in the values of Rg.  
 
 
 
 
 
At higher drug concentrations (100 mM to 200 mM), the features of 
scattering profiles of HSA-drug complexes are very different from 
that of low drug concentrations. There is appearance of a 
correlation peak in SANS profiles of HSA-drug systems. This 
correlation peak is attributed to the presence of repulsive micellar 
aggregates, which are formed at the higher drug concentrations 
(the concentrations are well above the respective cmc values). 
Therefore, the SANS data at high drug concentrations were fitted as 
a sum of contributions from free micelles and HSA-drug complexes 
26. The fitted parameters are listed in Table 1. The analysis indicates 
that a high drug concentration does not appear to affect the HSA-
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drug complexes (as the excess drug remains in solution as free 
micelles without disrupting the HSA-drug complexes).  Levis et al.29 
studied the influence of pH on the complex forming behaviour of 
amphiphilic drug nortryptyline hydrochloride and HSA, where they 
have reported adsorption of the drug on the protein at low drug 
concentrations and formation of drug aggregates at higher drug 
concentrations. At > 100 mM drug concentration, the correlation 
peak becomes more prominent indicating the presence of higher 
repulsive intermicellar interactions between the positively charged 
drug micelles. It is found that at higher drug concentrations the Rg 
value of polypeptide chain and the micellar dimensions remain the 
same, however, there is increase in effective particle charge (Z). An 
increase in scattering intensity at higher drug concentrations is due 
to the increase in number of free micelles. 
 
HSA + Drug HSA-drug 
complex 
parameters 
Micellar parameters 
 Rg(Å) ± 1 a (Å) 
± 1  
b=c (Å) 
± 1 
Z 
25mM AMT 52.88 - - - 
50mM AMT 55.15 - - - 
100mM AMT 55.03 95.59 10.93 - 
200mM AMT 55.65 95.66 10.59 13.15 
25mM PMT 44.59 - - - 
50mM PMT 47.53 - - - 
100mM PMT 57.15 97.98 10.53 - 
200mM PMT 57.55 98.15 9.25 10.28 
25mM IMP 42.14 - - - 
50mM IMP 44.47 - - - 
100mM IMP 55.12 92.23 9.82 - 
200mM IMP 55.01 98.51 9.45 12.54 
 
Table 1: Fitted parameters, i.e., semimajor axis (a), semiminor axis 
(b,c), radius of gyration (Rg), and effective particle charge (Z) of 
SANS analysis of HSA with respect to the concentration  of drugs (in 
every system the HSA concentration was maintained constant at 1% 
w/v). 
 
At low concentrations of drug (25mM and 50mM) the radius of 
gyration of HSA in presence of AMT increases upto a larger extent 
than in comparison to that of IMP and PMT (Table 1).  The 
scattering profile in Kratky plot of HSA-AMT complex is higher than 
that of HSA-IMP and HSA-PMT complexes at low drug 
concentrations (Figure 3 B). These morphological changes of HSA in 
presence of AMT are attributed to the slightly large hydrophobic 
backbone of the AMT in comparison to that of IMP and PMT.  There 
is literature agreement that initially the interaction between ionic 
compound and protein is ionic, causes the protein to unfold and 
exposes more binding sites 30,31. The non-polar amino acid side 
chains of protein interact with hydrophobic backbone of small 
molecules 20. The hydrophobic interaction of protein and small 
molecules leads to conformational change even when the 
concentration of ligand is remarkably low 32.  Higher hydrophobicity 
of AMT is reflected by the low critical micelle concentration of AMT 
in comparison to that of PMT and IMP 18. HSA shows maximum 
structural change in presence of AMT upto 50mM concentration 
while as in case of PMT and IMP maximum changes occur up to 
100mM, which is also in accordance with high hydrophobic nature 
of AMT. 
 
We have also performed DLS measurements to analyze the 
existence of different species in solution and to obtain the size of 
the drug-protein complexes. Figure 3C shows the size distribution of 
HSA solution ([HSA] = 1% (w/v)) in the presence and absence of 
amphiphilic drugs. The figure collects the hydrodynamic radii of the 
HSA(apo) and HSA-drug complexes, taken from the position of the 
peaks of the intensity distribution function, at different drug 
concentrations. The distribution obtained for pure HSA(apo) (1wt 
%) solution shows one peak and hydrodynamic radius of 3.73 nm, 
which is in agreement with the literature value 33. HSA-drug 
complexes at 25 and 50 mM drug concentrations (below cmc) also 
show only one peak, though the intensity and broadening of the 
peak indicate complex formation between the drug and HSA. The 
magnitude of the change in the hydrodynamic radius of HSA is 
sufficient to account for appreciable unfolding in the protein 
molecule. At 100 mM drug concentration, there is appearance of 
another small peak, which may be assigned to the existence of free 
drug aggregates. With further increase in the drug concentration 
(200 mM), two peaks can be perfectly distinguished, one 
attributable to the HSA-drug complexes and the other to the 
micelle-like structures formed by the drugs. This is in accordance to 
our SANS data, wherein also we obtained increase in size of HSA-
drug complexes at small drug concentrations, and at higher 
concentrations, the occurrence of free drug micelles. The different 
values in the sizes of the complexes obtained using DLS and SANS 
are expected because DLS measures structures along with its 
hydration 23. 
 
In an earlier study it has been reported that the unfolding in bovine 
serum album protein is caused by micelle-like aggregation of 
surfactant molecules in the complex, but in lysozyme the unfolding 
is due to the individual binding of the same surfactant molecules; 
this leads to the evidence that the model which fits to the protein-
surfactant complex depends on the type of protein 34. However, 
from both the studies (SANS and DLS) of HSA-drug complexes, it can 
be concluded that the type of model fitting to protein-amphiphile 
complexes depends also on the structure of the amphiphile as well.  
 
In order to explore how AMT/PMT/IMP binds to HSA, molecular 
docking was performed. HSA has previously been co-crystallised 
with several ligands. It has been reported that AMT binds to both 
site 1 and 2 of HSA, while PMT only binds to site 1 and IMP shows a 
preference for site 2 35-37. Diclofenac is one of the drugs that closely 
resemble the cationic ligands binding in the small cavity in site 1, 
where AMT and PMT docked, in an orientation similar to diclofenac 
(Figure 1). Diazepam was used as the probe for site 2 and its 
common structure was used as a template to dock AMT and IMP. 
The calculated binding energies were similar in each site and ranged 
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between HSA-AMT (-15.6 kcal/mol) and HAS-PMT (-13.2 kcal/mol) 
in site 1, HSA-AMT (-7.3 kcal/mol) and HSA-IMP (-6.7 kcal/mol) in 
site 2. The negative interaction energies suggest that the 
interactions are spontaneous and the morphology of hydrophobic 
moiety of the cationic ligands decides their binding fate. The 
complexes were then subjected to molecular dynamics simulations 
in order to extract comprehensive details concerning structural 
perturbations induced by the binding of cationic ligands to HSA. 
Three sets of statistically independent simulations for the HSA(apo) 
and each HSA-drug complex were run to refine the structures and 
investigate the morphological changes, occurring upon 
AMT/PMT/IMP binding. In total, 15 MD simulations were run up to 
500 ns each for HSA(apo) and HSA-drug complexes. Here we report 
the average of the three simulations. 
 
Figure 4: Left column: Cα Root mean-squared deviation (RMSD 
(nm)), Middle column: Radius of gyration (RG (nm)) and Right 
column: Solvent accessible surface area (SASA (nm2)) of HSA(apo) 
(black) and in complex with AMT-site1 (red), PMT (green), AMT-
site2 (orange) and IMP (blue) calculated from the simulations. 
Three simulations (dashed lines) for each system were run and the 
average values of the three simulations have been plotted (solid 
line). 
 HSA 
(apo) 
HSA-
AMT 
(site 1) 
HSA-
PMT 
(site 1) 
HSA-
AMT 
(site 2) 
HSA-
IMP 
(site 2) 
RMSD 
(nm) 
0.39 
(0.04) 
0.43 
(0.04) 
0.40 
(0.04) 
0.27 
(0.01) 
0.25 
(0.02) 
Rg  
(nm) 
2.69 
(0.02) 
2.75 
(0.02) 
2.72 
(0.02) 
2.66 
(0.02) 
2.65 
(0.01) 
SASA 
(nm2) 
325.5 
(3.1) 
332.1 
(3.0) 
330.2 
(3.0) 
330.5 
(3.1) 
326.7 
(3.0) 
 
Table 2: Average RMSD, Rg and SASA values over the course of the 
final 100ns of the simulation run. The values have been averaged 
over 3 simulation runs. Standard deviation is tabulated in 
parenthesis. 
The stability of simulations was assessed by calculating the Cα root 
mean-squared deviation (RMSD). The radius of gyration (Rg) and 
solvent accessible surface (SASA) area was also monitored over the 
course of the simulation time to assess the tertiary structure of the 
systems. The values of RMSD, Rg and SASA for the final 100ns are 
tabulated in Table 2. The radius of gyration (Rg) measures the 
compactness of a protein structure. If a structure is folded, the Rg 
values will be stable over the course of the simulation. Native HSA 
maintains its tertiary structure during the simulation, although the 
cationic complexes stabilize at higher Rg values (Figure 4 middle 
column). The calculated solvent-accessible surface area (SASA) for 
the complexes is comparable or greater than that for native HSA 
indicating that the binding of cationic ligands increases the exposed 
areas (Figure 4 left column). AMT, when bound in site 1 displayed 
greatest RMSD, while the most compact structure based on Rg and 
SASA analysis was that of HSA(apo). A detailed view of 
conformational perturbation was also obtained by measuring the 
minimum distance of ion-pair interactions that exist at the interface 
between the subdomains (Supplementary figure S2B). A 
simultaneous, irreversible loss of multiple ion-pair interactions is an 
indicator of unidirectional conformational drift leading to a possible 
localized loss of secondary structure (Supplementary figure S3). We 
define these ion pair interactions collectively to be reflective of the 
core of the HSA structure. A total of ten ion pair interactions were 
monitored including R117-E520, R485-E383, R472-D494, R428-
D183, R410-E492, R348-E383, R10-D259, R209-E354, K432-E184 
and K432-D187. While these ion-pair interactions are reversibly 
maintained in the HSA(apo) simulations, the binding of cationic 
drugs has a noticeable destabilizing effect on most of them in the 
complex (Supplementary figure S2C). R485-E383 ion-pair 
interaction is however maintained in all systems, while R117-E520 
interaction is lost only when the drugs are bound in site 2. 
Furthermore, a comparison of the per-residue root mean squared 
deviation (Supplementary figure S4) highlights the conformational 
drift in the drug-HSA complexes. Greater root mean squared 
deviation of residues is observed in the core of the complexes, as 
when compared with the HSA(apo). The root mean squared 
fluctuation also confirms that the drugs, when bound in site 1 
exhibited pronounced structural effects on the protein than when 
bound in site 2 (Supplementary figure S5). The overall results are 
consistent with the experimental observation that binding of 
cationic ligands brings about a conformational change upon binding 
with HSA. 
Conclusions 
We have studied the effect of three cationic amphiphillic drugs 
(AMT/IMP/PMT) on conformation of human serum albumin (HSA). 
At low concentrations, the drug molecules get individually bound to 
HSA, and hence, the sub-domains of protein start separating from 
each other, resulting in increase in values of Rg (unfolding of 
polypeptide chain). With increase in drug concentration, there is no 
change in the dimensions of HSA-drug complexes. HSA in presence 
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of higher drug concentrations has protein-drug complex structure 
with free micelles of drugs, i.e., the HSA-drug complexes coexist 
with free drug micelles. Both SANS and DLS studies suggest that the 
protein gets unfolded in presence of the cationic amphiphillic drugs, 
and after saturation of protein, there is formation of free micelles 
of the drugs (Supplementary figure S6). Molecular docking reveals 
that the cavities in sub-domain IIA (site 1) and IIIA (Site 2) of HSA 
represent the preferred binding sites to the cationic amphiphilic 
drugs. Thus, the hydrophobic backbone of the amphiphilic 
molecules (viz., the cationic drugs in the present case) plays an 
important role in their binding with HSA. 
Experimental 
Materials and methods  
Amitrityline hydrochloride (AMT), promethazine hydrochloride 
(PMT), imipramine hydrochloride (IMP), and human serum albumin 
(HSA) were purchased from Sigma and used without further 
purification. Human serum albumin was essentially fatty acid free. 
All other reagents were of analytical grade. All the experiments 
were carried out in Tris hydrochloride buffer solution of pH=7.4. 
Small-angle neutron scattering (SANS) measurements 
Samples for SANS experiments were prepared by dissolving known 
amounts of HSA and HSA-drug mixtures in buffer solution of D2O. 
The use of D2O as a solvent (instead of H2O) provides good contrast 
for the hydrogenous protein in neutron experiments. SANS is a 
diffraction experiment, which involves scattering of a 
monochromatic beam of neutrons from the sample and measuring 
the scattered neutron intensity as a function of the scattering angle. 
The wave-vector transfer Q (= 4πsinθ/λ, where λ is the incident 
neutron wavelength and 2θ is the scattering angle) in these 
experiments is small, typically in the range of 10-3 to 1.0 Å. The 
wavelength of neutrons used for these experiments are usually 
4−10  Å. SANS experiments were carried out at Dhruva reactor, 
BARC, Mumbai, India 38. 
Data analysis 
SANS experiments measure the coherent differential scattering 
cross-section (dΣ/dΩ) as a function of wave-vector transfer Q. For a 
system of mono-dispersed particles, it is given by 39. 
 
d∑
dΩ
(Q) = NPVP
2(ρP − ρS )
2[< F(Q)2 > + < F(Q)>2 [SP (Q)−1]+ B  (1) 
 
where Vp is the volume of the particle, Pρ  and sρ  are, 
respectively, the scattering length densities of the particle and the 
solvent. Np is the number density of the particles. F(Q) is the single 
particle form factor and is decided by the shape and size of the 
particle. Sp(Q) is the interparticle structure factor, which depends 
on the spatial arrangement of particles and on the interparticle 
interactions. Interparticle interference effects are negligible in case 
of dilute solutions (i.e. Sp(Q)∼1). The scattered neutron intensity in 
the SANS experiment depends on the square of the difference 
between the average scattering length density of the particle and 
the average scattering length density of the solvent (i.e., ( Pρ -
sρ )2). This term is referred to as the contrast factor. The scattering 
length density is positive for deuterium and negative for hydrogen, 
which makes SANS ideal for studying the structural aspects of 
hydrogenous materials such as protein solutions. B is a constant 
term that represents the incoherent scattering background due to 
hydrogen in the sample. In case of charged colloidal systems, such 
as protein solutions, the SANS data show a correlation peak due to 
interparticle structure factor indicating the presence of significant 
interaction between the colloids. 
 
Modelling for HSA 
In case of protein solutions of low concentrations, Eq. (1) for such 
systems becomes 
 
d∑
dΩ
(Q) = NPVP
2 (ρP − ρS )
2 < F(Q)2 > +B    (2) 
 
The form factor for prolate ellipsoidal shape having semi-major and 
minor axes a and b=c can be given by 
             
< F(Q)2 >= F(Q,µ)dµ
0
1
∫






2
  (3) 
 
F(Q,µ) = 3(sin x − x cos x)
x3
   (4) 
 
x =Q[a2µ 2 +b2 (1− µ 2 )]1/2    (5) 
 
where a and b represent the semi-major and the semi-minor axes 
of the ellipsoidal protein macromolecules, respectively, and µ is the 
cosine of the angle between the directions of a and the wave-
vector transfer Q. 
  
Modelling for HSA-drug conjugates 
The unfolding of protein in the presence of drugs is believed to be 
the opening of the globular protein structure into a random coil 
Gaussian conformation of the unfolded polypeptide chain. In this 
case, the scattering cross-section is given as 
 
d∑
dΩ
(Q) = Io Q
2Rg
2 −1+ exp(−Q2Rg
2 )  / QRg( )
4
  (6) 
 
where Rg is the radius of gyration of the unfolded protein 
polypeptide chain. 
 
The interparticle structure factor Sp(Q) for the charged micelles is 
calculated by Hayter and Penfold 40 analysis from the Ornstein-
Zernike equation under the rescaled mean spherical approximation 
41. The data has been analyzed by comparing the scattering from 
different models to the experimental data (instrumental corrections 
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were also made). The modeled scattering profiles were smeared by 
the appropriate resolution function to compare with the measured 
data. The fitted parameters in the analysis were optimized by 
means of nonlinear least-square fitting program 42, 43. 
 
Dynamic light scattering (DLS) 
Dynamic light scattering measurements were performed using a 
Laser-Spectroscatter 201 (RiNA GmbH, Berlin, Germany). In DLS 
measurements, a beam of laser is guided towards the sample under 
investigation, with a fixed detection arrangement of 90° to the 
center of the cell and the fluctuation in the intensity of the 
scattered light is measured. 
 
Molecular docking and simulations 
Structure of the HSA (PDB ID: 4Z69 and 2BXF) was downloaded 
from the protein data bank (http://www.rcsb.org./pdb). These 
structures were chosen because they are in complex with 
Diclofenac (4Z69, site 1) and Diazepam (2BXF, site 2), whose 
chemical skeleton resembles that of the studied cationic drugs. The 
HSA was prepared by removing diclofenac from the 4Z69 structure. 
The PDB files of drugs were downloaded from Drugbank (AMT 
DB00321; IMP D00458; PMT DB01069). The drugs were docked 
using the docking module in the ICM-Pro software 
(www.molsoft.com). Template-based docking protocol was used. 
The spatial orientation of the common substructure in the chemical 
skeletons of Diclofenac (site 1) and Diazepam (site 2) were selected 
as reference templates to dock the cationic drugs. Grid maps were 
generated around the templates, which defined a binding site 
encompassed in a grid of 30 x 30 x 30Å3. Docking was run with an 
effort of 5, storing all alternative conformations. A maximum of 25 
docked conformations were generated. The final conformation was 
chosen based on strongest interaction energy and the lowest rmsd 
values from the templates’ common substructure. Visualization of 
the docked poses was done by using Pymol 44 and ICM-Pro Molsoft 
molecular modelling package. Parameters for the drugs were 
generated using antechamber software45. The complexes were set 
up using xleap employing ff14sb forcefield46 for protein and GAFF 
for the drugs. The solvated systems were solvated using TIP3P 47 
water and the edge of the box was set to at least 1 nm from the 
closest solute atom. The system was neutralised using K+ and Cl- 
ions. The protocol was identical for all systems. Each system was 
minimized and relaxed under NPT conditions for 5ns at 1 atm. The 
temperature was ramped upto 298K using a timestep of 4 fs, rigid 
bonds, a cut-off of 0.9 nm and particle mesh ewalds summation 
switched on for long-range electrostatics. Only the solvent and ions 
were allowed to move during the equilibration. The heavy atoms of 
the protein and ligand atoms were constrained by a spring constant 
set at 1 kcal/mol/Å2. The production simulations were run using 
ACEMD 48 molecular dynamics engine in the NVT ensemble using a 
Langevin thermostat with a daming of 0.1 ps-1 and hydrogen mass 
repartitioning scheme to achieve time steps of 4fs 49. 3 sets of 
simulations were run for 500 ns, for each system starting from 
different velocities to improve the statistics. Average rmsd of the 3 
simulations was calculated and the individual simulation, closest to 
the average value, was chosen for further structural analysis. The 
rmsd values for each simulation are presented in Table S1. 
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